We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
Nicotinic acetylcholine receptors: an overview on drug discovery.
Expert Opinion on Therapeutic Targets 2009 April
BACKGROUND: Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels that participate in many physiological functions. Receptors result from the assembly of five homologous or heterologous subunits that form the ligand-binding site and an ionic pore. In vertebrates, 17 subunits have been identified, alpha (1 - 10), beta (1 - 4), gamma, delta and epsilon. Assembly of different subunit combinations allows a diversity of physiological and pharmacological properties.
OBJECTIVE: To review the putative involvement of nAChRs in several diseases.
METHODS: We discuss the expression pattern of the subunits, the pharmacological tools for distinguishing them and their role in pathogenesis.
RESULTS/CONCLUSION: Long-standing efforts in this field should soon result in the finding of new molecules that might be applicable to situations ranging from neurological diseases to immune treatments.
OBJECTIVE: To review the putative involvement of nAChRs in several diseases.
METHODS: We discuss the expression pattern of the subunits, the pharmacological tools for distinguishing them and their role in pathogenesis.
RESULTS/CONCLUSION: Long-standing efforts in this field should soon result in the finding of new molecules that might be applicable to situations ranging from neurological diseases to immune treatments.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app